Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mavis Donnelly

Psychiatry Tucson, AZ Medical Doctor

NPI 1245320647 CMS profile 10827

7345 E Tanque Verde Rd, Tucson, AZ 85715

Open in the dashboard

General payments

$3,049

159 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mavis Donnelly of Tucson, AZ is reported in the CMS Open Payments database as having received $3,049 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $480 18
2024 General $354 15
2023 General $467 20
2022 General $624 31
2021 General $546 32
2020 General $387 32
2019 General $190 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mavis Donnelly
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mavis Donnelly were reported at $480. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mavis Donnelly Psychiatry median Middle half National median
2019 $190 $184 $59–$605 $163
2020 $387 $119 $36–$372 $114
2021 $546 $143 $43–$576 $132
2022 $624 $153 $50–$590 $149
2023 $467 $170 $56–$651 $160
2024 $354 $179 $57–$673 $164
2025 $480 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,076 56 payments
  2. Sunovion Pharmaceuticals Inc. $468 24 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $259 13 payments
  4. Lundbeck LLC $186 8 payments
  5. Teva Pharmaceuticals USA, Inc. $169 6 payments
  6. ITI, Inc. $131 6 payments
  7. Allergan Inc. $129 17 payments
  8. Alkermes, Inc. $109 5 payments
  9. Bausch Health US, LLC $106 5 payments
  10. Janssen Pharmaceuticals, Inc $103 5 payments
  11. Other $312 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,049 159 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $901 49 payments
  2. LATUDA $468 24 payments
  3. VRAYLAR Neuroscience $303 24 payments
  4. TRINTELLIX $212 10 payments
  5. REXULTI $186 8 payments
  6. LYBALVI $109 5 payments
  7. ARISTADA Cns $109 5 payments
  8. ARISTADA Cns $109 5 payments
  9. Austedo XR $109 4 payments
  10. APLENZIN $106 5 payments
  11. Other $949 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

898

Median for Psychiatry & Neurology: 100

Drug cost

$85,852

Median for Psychiatry & Neurology: $2,986

Branded share of claims

42.1%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Wellbutrin Xl Bupropion Hcl Brand 11 $62,617
Vyvanse Lisdexamfetamine Dimesylate Brand 14 $5,126
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 143 $4,913
Venlafaxine Hcl Er Venlafaxine Hcl Brand 119 $3,228
Bupropion Xl Bupropion Hcl Brand 57 $2,315
Lamotrigine Generic 74 $1,773
Mirtazapine Generic 40 $1,199
Duloxetine Hcl Generic 28 $1,005
Clonazepam Generic 71 $569
Bupropion Hcl Sr Bupropion Hcl Brand 18 $559

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $102
$102 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $73
$73 — —
REXULTI
  • Lundbeck LLC $65
$65 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $52
$52 — —
CAPLYTA
  • ITI, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record